What question did this study set out to answer?

To develop a platform identifying small molecule inhibitors of ELOVL1 that impact VLCFA synthesis in adrenoleukodystrophy.

May 9, 2026Open Access

A Comprehensive Discovery Platform for ELOVL1 Small Molecule Inhibitors Targeting Very Long Chain Fatty Acid Synthesis in Adrenoleukodystrophy

Key Points

To develop a platform identifying small molecule inhibitors of ELOVL1 that impact VLCFA synthesis in adrenoleukodystrophy.
Utilized a comprehensive discovery platform for screening ELOVL1 inhibitors.
Analyzed the effect of identified inhibitors on VLCFA levels, particularly C26:0.
Investigated the correlation of VLCFA accumulation with neurological symptoms of ALD.
Identified multiple ELOVL1 small molecule inhibitors with significant reduction in C26:0 levels.
Demonstrated that the inhibitors effectively decreased VLCFA accumulation in affected tissues.
Observed improvement in biochemical markers associated with ALD.

Abstract

Adrenoleukodystrophy (ALD or X-ALD) is a rare devastating neurological disease caused by mutations in the ATP binding cassette D1 (ABCD1) gene, product of which is involved in the transport of Very Long Chain Fatty Acids (VLCFAs) into peroxisome for degradation by -oxidation.Deficiency in ABCD1 results in VLCFAs accumulation in many tissues, including the brain and spinal cord.Elevated VLCFA levels, specifically C26:0, are consistent biochemical markers of ALD and are implicated in the ALD

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Holley et al. (Fri,) studied this question.

synapsesocial.com/papers/69fececcb9154b0b828761ab https://doi.org/https://doi.org/10.1016/j.jbc.2026.113103

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper